Sunstone makes €5 million investment into Finnish women’s health company Forendo Pharma to finance clinical studies in endometriosis

Sunstone Life Science Ventures today announced its first investment out of its Life Science Ventures Fund IV into Forendo Pharma, a Finnish clinical stage drug development company focusing on novel treatments in women’s health.

The investment is designated to finance the continuation of Forendo Pharma’s positive Phase Ia study in post-menopausal women into Phase Ib in pre-menopausal women, and later Phase II for the treatment of endometriosis.

Press inquiries should be adressed to: